591 related articles for article (PubMed ID: 18202967)
21. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
[TBL] [Abstract][Full Text] [Related]
22. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
23. Treatment of high-risk older persons with lipid-lowering drug therapy.
Aronow WS
Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
[TBL] [Abstract][Full Text] [Related]
24. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids.
Langer RD; Friedman AJ
J Reprod Med; 2006 Aug; 51(8):610-6. PubMed ID: 16967629
[TBL] [Abstract][Full Text] [Related]
25. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
26. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
Mann D; Reynolds K; Smith D; Muntner P
Ann Pharmacother; 2008 Sep; 42(9):1208-15. PubMed ID: 18648016
[TBL] [Abstract][Full Text] [Related]
27. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
30. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort).
Gardette V; Bongard V; Dallongeville J; Arveiler D; Bingham A; Ruidavets JB; Amouyel P; Haas B; Ducimetière P; Ferrières J
Am J Cardiol; 2009 Feb; 103(3):381-6. PubMed ID: 19166693
[TBL] [Abstract][Full Text] [Related]
31. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study.
Mackey RH; Kuller LH; Sutton-Tyrrell K; Evans RW; Holubkov R; Matthews KA
Arch Intern Med; 2005 Mar; 165(5):510-5. PubMed ID: 15767525
[TBL] [Abstract][Full Text] [Related]
32. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
33. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
35. The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.
Autier P; Creplet J; Vansant G; Brohet C; Paquot N; Muls E; Mullie P; Grivegnée AR
Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):456-62. PubMed ID: 14671469
[TBL] [Abstract][Full Text] [Related]
36. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
Mosca L; Merz NB; Blumenthal RS; Cziraky MJ; Fabunmi RP; Sarawate C; Watson KE; Willey VJ; Stanek EJ
Circulation; 2005 Feb; 111(4):488-93. PubMed ID: 15687138
[TBL] [Abstract][Full Text] [Related]
37. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
38. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Williams B; Lacy PS; Cruickshank JK; Collier D; Hughes AD; Stanton A; Thom S; Thurston H;
Circulation; 2009 Jan; 119(1):53-61. PubMed ID: 19103995
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with changes in serum total cholesterol levels over 7 years in middle-aged New Zealand men and women: a prospective study.
Metcalf PA; Scragg RK; Swinburn BA; Shaw LM
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):298-305. PubMed ID: 11887426
[TBL] [Abstract][Full Text] [Related]
40. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
